Mechanistic basis of using body size and maturation to predict clearance in humans

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 1, 2009, Pages 25-36

  Anderson, Brian J ^a   Holford, Nick H G ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Body composition; Clearance; Maturation; Pharmacokinetics; Size

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CREATININE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ETIRACETAM; MIDAZOLAM; MORPHINE; PARACETAMOL; TRAMADOL; VANCOMYCIN; XENOBIOTIC AGENT;

ALLOMETRY; BODY COMPOSITION; BODY FAT; BODY SIZE; BODY SURFACE; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; GLOMERULUS FILTRATION RATE; HUMAN; LEAN BODY WEIGHT; MATURATION; NEWBORN SEPSIS; PREDICTION; REVIEW; SCALE UP; TONIC CLONIC SEIZURE;

EID: 67649415182     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.25     Document Type: Review

References (85)

1. Holford, N. H. G.: A size standard for pharmacokinetics. Clinical Pharmacokinetics, 30: 329-332 (1996).
2. Bonate, P. L.: The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharmaceutical Research, 16: 709-717 (1999).
3. Friis-Hansen, B.: Body water compartments in children: changes during growth and related changes in body composition. Pediatrics, 28: 169-181 (1961).
4. White, C. R.and Seymour, R. S.: Allometric scaling of mammalian metabolism. J. Exp. Biol., 208: 1611-1619 (2005).
5. Savage, V. M., Gillooly, J. F., Woodruff, W. H., West, G. B., Allen, A. P., Enquist, B. J. and Brown, J. H.: The predominance of quarter-power scaling in biology. Functional Ecology, 18: 257-282 (2004).
6. Sarrus, F. and Rameaux, J. F.: Rapport sur un meá moire adresseá aà l'Acadeá mie Royale de Meá decine. Bull Acad. Roy. Med. Belg, 3: 1094 (1839).
7. McMahon, T. A.: Scaling physiological time. Lectures on mathematics in the life sciences, 13: 131-133 (1980).
8. Dawson, W. T.: Relations between age and weight and dosages of drugs. Ann. Intern. Med., 13: 1594-1613 (1940).
9. Crawford, J. D., Terry, M. E. and Rourke, G. M.: Simplification of drug dosage calculation by application of the surface area principle. Pediatrics, 5: 783-790 (1950).
10. Kleiber, M.: Body size and metabolism. Hilgardia, 6: 315-333 (1932).
11. Peters, H. P.: Chpt 4. Physiological correlates of size. In E. Beck, H. J. B. Birks and E. F. Conner (eds): The Ecological Implications of Body Size, Cambridge University Press, Cambridge, 1983, pp. 48-53.
12. Brody, S., Proctor, R. C. and Ashworth, U. S.: Basal metabolism, endogenous nitrogen, creatinine, and sulphur excretions as functions of body weight. Univ. Mo. Agric. Exp. Sta. Res. Bull., 220: 1-40 (1934).
13. Stahl, W. R.: Scaling of respiratory variables in mammals. J. Appl. Physiol., 22: 453-600 (1967).
14. Gillooly, J. F., Brown, J. H.,West, G. B., Savage, V. M. and Charnov, E. L.: Effects of Size and Temperature on Metabolic Rate. Science, 293: 2248-2251 (2001).
15. Savage, V. M.: Improved approximations to scaling relationships for species, populations, and ecosystems across latitudinal and elevational gradients. J. Theor. Biol., 227: 525-534 (2004).
16. West, G. B.and Brown, J. H.: The origin of allometric scaling laws in biology from genomes to ecosystems: towards a quantitative unifying theory of biological structure and organization. J. Exp. Biol., 208: 1575-1592 (2005).
17. West, G. B., Brown, J. H. and Enquist, B. J.: A general model for the origin of allometric scaling laws in biology. Science, 276: 122-126 (1997).
18. West, G. B., Brown, J. H. and Enquist, B. J.: The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science, 284: 1677-1679 (1999).
19. Anderson, B. J.and Holford, N. H.: Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol., 48: 303-332 (2008).
20. Cheymol, G.: Effects of obesity on pharmacokinetics implications for drug therapy. Clin. Pharmacokinet., 39: 215-231 (2000).
21. Han, P. Y., Duffull, S. B., Kirkpatrick, C. M. and Green, B.: Dosing in obesity: a simple solution to a big problem. Clin. Pharmacol. Ther., 82: 505-508 (2007).
22. Ewy, G. A., Groves, B. M., Ball, M. F., Nimmo, L., Jackson, B. and Marcus, F.: Digoxin metabolism in obesity. Circulation, 44: 810-814 (1971).
23. Abernethy, D. R., Greenblatt, D. J., Divoll, M. and Shader, R. I.: Prolonged accumulation of diazepam in obesity. J. Clin. Pharmacol., 23: 369-376 (1983).
24. Janmahasatian, S., Duffull, S. B., Ash, S.,Ward, L. C., Byrne, N. M. and Green, B.: Quantification of lean bodyweight. Clin. Pharmacokinet., 44: 1051-1065 (2005).
25. Duffull, S. B., Dooley, M. J., Green, B., Poole, S. G. and Kirkpatrick, C. M.: A standard weight descriptor for dose adjustment in the obese patient. Clin. Pharmacokinet., 43: 1167-1178 (2004).
26. Rhodin, M. M., Anderson, B. J., Peters, A. M., Coulthard, M. G., Wilkins, B., Cole, M., Chatelut, E., Grubb, A., Veal, G. J., Keir, M. J. and Holford, N. H. G.: Human renal function maturation; a quantitative description using weight and postmenstrual age. Pediatric Nephrology in press (2008).
27. Johnson, T. N.: Modelling approaches to dose estimation in children. Br. J. Clin. Pharmacol., 59: 663-669 (2005).
28. Johnson, T. N.: The problems in scaling adult drug doses to children. Arch. Dis. Child., Epub Oct 12 (2007).
29. Edginton, A. N., Schmitt, W., Voith, B. and Willmann, S.: A mechanistic approach for the scaling of clearance in children. Clinical. Pharmacokinetics., 45: 683-704 (2006).
30. Anderson, B. J., van Lingen, R. A., Hansen, T. G., Lin, Y. C. and Holford, N. H.: Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology, 96: 1336-1345 (2002).
31. Hill, A. V.: The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol., 14: ivvii (1910).
32. Tod, M., Jullien, V. and Pons, G.: Facilitation of drug evaluation in children by population methods and modelling. Clin. Pharmacokinet., 47: 231-243 (2008).
33. Richards, F. J.: A flexible growth function for empirical use. J. Exp. Bot., 10: 290-301 (1959).
34. Engle, W. A.: Age terminology during the perinatal period. Pediatrics, 114: 1362-1364 (2004).
35. Ivanchuk, S. M., Eng, C., Cavenee, W. K. and Mulligan, L. M.: The expression of RET and its multiple splice forms in developing human kidney. Oncogene, 14: 1811-1818 (1997).
36. Pacifici, G. M., Sawe, J., Kager, L. and Rane, A.: Morphine glucuronidation in human fetal and adult liver. Eur. J. Clin. Pharmacol., 22: 553-558 (1982).
37. Pacifici, G. M., Franchi, M., Giuliani, L. and Rane, A.: Development of the glucuronyltransferase and sulphotransferase towards 2-naphthol in human fetus. Dev. Pharmacol. Ther., 14: 108-114 (1989).
38. Koukouritaki, S. B., Manro, J. R., Marsh, S. A., Stevens, J. C., Rettie, A. E.,McCarver, D. G. and Hines, R. N.: Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther., 308: 965-974. Epub 2003 Nov 21. (2004).
39. Allegaert, K., Anderson, B. J., Verbesselt, R., Debeer, A., de Hoon, J., Devlieger, H., van den Anker, J. N. and Tibboel, D.: Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P450 2D6 activity. Br. J. Anaesth., 231-239 (2005).
40. Paap, C. M. and Nahata, M. C.: Prospective evaluation of ten methods for estimating creatinine clearance in children with varying degrees of renal dysfunction. J. Clin. Pharm. Ther., 20: 67-73 (1995).
41. Cole, M., Price, L., Parry, A., Keir, M. J., Pearson, A. D., Boddy, A. V. and Veal, G. J.: Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics. Br. J. Cancer., 90: 60-64 (2004).
42. Calder, W. A. and Braun, E. J.: Scaling of osmotic regulation in mammals and birds. Am. J. Physiol., 244: R601-606 (1983).
43. Singer, M. A. and Morton, A. R.: Mouse to elephant: biological scaling and Kt/V. Am. J. Kidney. Dis., 35: 306-309 (2000).
44. Singer, M. A.: Of mice and men and elephants: metabolic rate sets glomerular filtration rate. Am. J. Kidney. Dis., 37: 164-178 (2001).
45. Edwards, N. A.: Scaling of renal functions in mammals. Comp. Biochem. Physiol. A, 52: 63-66 (1975).
46. Heilbron, D. C., Holliday, M. A., al-Dahwi, A. and Kogan, B. A.: Expressing glomerular filtration rate in children. Pediatr Nephrol., 5: 5-11 (1991).
47. Stevens, L. A., Coresh, J., Greene, T. and Levey, A. S.: Assessing kidney function--measured and estimated glomerular filtration rate. N. Engl. J. Med., 354: 2473-2483 (2006).
48. Guignard, J. P. and Drukker, A.:Why do newborn infants have a high plasma creatinine? Pediatrics, 103: e49 (1999).
49. Cockcroft, D. and Gault, M.: Prediction of creatinine clearance from serum creatinine. Nephron, 16: 31-41 (1976).
50. Schwartz, G. J.: Does kL/PCr estimate GFR, or does GFR determine k? Pediatr. Nephrol., 6: 512-515 (1992).
51. Schwartz, G. J., Haycock, G. B., Edelmann, C. M., Jr. and Spitzer, A.: A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics, 58: 259-263 (1976).
52. Schwartz, G. J., Feld, L. G. and Langford, D. J.: A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J. Pediatr., 104: 849-854 (1984).
53. Brion, L. P., Fleischman, A. R., McCarton, C. and Schwartz, G. J.: A simple estimate of glomerular filtration rate in low birth weight infants during the first year of life: noninvasive assessment of body composition and growth. J. Pediatr., 109: 698-707 (1986).
54. Hellerstein, S., Alon, U., Blowey, D., Kaplan, R. and Warady, B. A.: Use of serum creatinine concentration for estimation of glomerular filtration rate. Am. J. Dis. Child., 147: 719-720 (1993).
55. Hellerstein, S., Alon, U. and Warady, B. A.: Creatinine for estimation of glomerular filtration rate. Pediatr Nephrol., 6: 507-511 (1992).
56. Gallini, F., Maggio, L., Romagnoli, C., Marrocco, G. and Tortorolo, G.: Progression of renal function in preterm neonates with gestational age
57. Miall, L. S., Henderson, M. J., Turner, A. J., Brownlee, K. G., Brocklebank, J. T., Newell, S. J. and Allgar, V. L.: Plasma creatinine rises dramatically in the first 48 hours of life in preterm infants. Pediatrics, 104: e76 (1999).
58. Holford, N. H.: Target concentration intervention: beyond Y2K. Br. J. Clin. Pharmacol., 52(Suppl 1): 55S-59S (2001).
59. Grimsley, C. and Thomson, A. H.: Pharmacokinetics and dose requirements of vancomycin in neonates. Arch. Dis. Child Fetal Neonatal Ed., 81: F221-227 (1999).
60. Anderson, B. J., Allegaert, K., Van den Anker, J. N., Cossey, V. and Holford, N. H.: Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol., 63: 75-84 (2007).
61. Bouwmeester, N. J., Anderson, B. J., Tibboel, D. and Holford, N. H.: Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth., 92: 208-217 (2004).
62. Toublanc, N., Sargentini-Maier, M. L., Lacroix, B., Jacqmin, P. and Stockis, A.: Retrospective population pharmacokinetic analysis of levetiracetam in children and adolescents with epilepsy: dosing recommendations. Clin. Pharmacokinet., 47: 333-341 (2008).
63. Toublanc, N., Lovern, M., Sargentini-Maier, M. L. and Stockis, A.: Population pharmackinetic analysis of levetiracetam in pediatric patients with epilepsy aged 1 month to 16 years, 8th European Congress on Epileptology, Berlin, 2008.
64. Kearns, G. L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D. L., Leeder, J. S. and Kauffman, R. E.: Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med., 349: 1157-1167. (2003).
65. Hines, R. N. and McCarver, D. G.: The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J. Pharmacol. Exp. Ther., 300: 355-360 (2002).
66. Johnsrud, E. K., Koukouritaki, S. B., Divakaran, K., Brunengraber, L. L., Hines, R. N. and McCarver, D. G.: Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther., 307: 402-407 (2003).
67. van der Marel, C. D., Anderson, B. J., van Lingen, R. A., Holford, N. H. G., Pluim, M. A. L., Jansman, F. G. A., van den Anker, J. N. and Tibboel, D.: Paracetamol and metabolite pharmacokinetics in infants. European Journal of Clinical Pharmacology, 59: 243-251 (2003).
68. McCarver, D. G. and Hines, R. N.: The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther., 300: 361-366 (2002).
69. de Wildt, S. N., Kearns, G. L., Leeder, J. S. and van den Anker, J. N.: Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet., 36: 439-452. (1999).
70. Stone, A. N., Mackenzie, P. I., Galetin, A., Houston, J. B. and Miners, J. O.: Isoform selectivity and kinetics of morphine 3-and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug. Metab. Dispos., 31: 1086-1089 (2003).
71. Anand, K. J., Anderson, B. J., Holford, N. H., Hall, R. W., Young, T., Shephard, B., Desai, N. S. and Barton, B. A.: Morphine pharmacokinetics and pharmacodynamics in preterm and term neonates: secondary results from the NEOPAIN trial. Br. J. Anaesth., 101: 6806-689 (2008).
72. Treluyer, J. M., Gueret, G., Cheron, G., Sonnier, M. and Cresteil, T.: Developmental expression of CYP2C and CYP2C-dependent activities in the human liver: in-vivo/in-vitro correlation and inducibility. Pharmacogenetics, 7: 441-452 (1997).
73. Vieira, I., Sonnier, M. and Cresteil, T.: Developmental expression of CYP2E1 in the human liver. Hypermethylation control of gene expression during the neonatal period. European Journal of Biochemistry, 238: 476-83 (1996).
74. Burchell, B., Coughtrie, M., Jackson, M., Harding, D., Fournel-Gigleux, S., Leakey, J. and Hume, R.: Development of human liver UDP-glucuronosyltransferases. Dev. Pharmacol. Ther., 13: 70-77 (1989).
75. Onishi, S., Kawade, N., Itoh, S., Isobe, K. and Sugiyama, S.: Postnatal development of uridine diphosphate glucuronyltransferase activity towards bilirubin and 2-aminophenol in human liver. Biochem. J., 184: 705-707 (1979).
76. Lynn, A., Nespeca, M. K., Bratton, S. L., Strauss, S. G. and Shen, D. D.: Clearance of morphine in postoperative infants during intravenous infusion: the influence of age and surgery. Anesth. Analg., 86: 958-963 (1998).
77. Pokela, M. L., Olkkola, K. T., Seppala, T. and Koivisto, M.: Agerelated morphine kinetics in infants. Dev. Pharmacol. Ther., 20: 26-34 (1993).
78. Peters, J. W., Anderson, B. J., Simons, S. H., Uges, D. R. and Tibboel, D.: Morphine metabolite pharmacokinetics during venoarterial extra corporeal membrane oxygenation in neonates. Clinical. Pharmacokinetics., 45: 705-714 (2006).
79. Court, M. H., Duan, S. X., von Moltke, L. L., Greenblatt, D. J., Patten, C. J., Miners, J. O. and Mackenzie, P. I.: Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J. Pharmacol. Exp. Ther., 299: 998-1006 (2001).
80. Anderson, B. J., Woollard, G. A. and Holford, N. H.: Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur. J. Clin. Pharmacol., 57: 559-569 (2001).
81. Anderson, B. J., Holford, N. H. G., Woollard, G. A. and Chan, P. L.: Paracetamol plasma and cerebrospinal fluid pharmacokinetics in children. Br. J. Clin. Pharmacol., 46: 237-243 (1998).
82. Anderson, B. J., Pons, G., Autret-Leca, E., Allegaert, K. and Boccard, E.: Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr. Anaesth., 15: 282-292. (2005).
83. Palmer, G. M., Atkins, M., Anderson, B. J., Smith, K. R., Culnane, T. J., McNally, C. M., Perkins, E. J., Chalkiadis, G. A. and Hunt, R. W.: I.V. acetaminophen pharmacokinetics in neonates after multiple doses. Br. J. Anaesth., 101: 523-530 (2008).
84. Gaganis, P., Miners, J. O., Brennan, J. S., Thomas, A. and Knights, K. M.: Human renal cortical and medullary UDPglucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J. Pharmacol. Exp. Ther., 323: 422-430 (2007).
85. Bowalgaha, K. and Miners, J. O.: The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br. J. Clin. Pharmacol., 52: 605-609 (2001).